Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non-Irritative Concentrations

These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non-immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4-6 weeks post-reaction; whereas beyond 6 months, false-negative results increase. For chemotherapy-related reactions, earlier testing (within 2 weeks) remains necessary due to treatment urgency. The previously published multicenter ENDA study established the international reference method for positive immediate intradermal test reading: injection of exactly 0.02 mL with a wheal at 20 min measuring ≥ initial wheal +3 mm, representing a major standardization achievement. For patch testing, exact active ingredient concentrations must be systematically documented. When tablets are crushed and diluted at 30% in petrolatum, significant variability in final concentrations has been observed. The guidelines present validated nonirritant concentrations for major drug classes including antibiotics, contrast media, anesthetics, proton pump inhibitors, chemotherapies, and biologicals. Specific recommendations are based on negative controls demonstrating specificity, while conditional recommendations are provided when few or no negative controls are available. Risk stratification algorithms now allow direct drug provocation testing for mild maculopapular exanthema, bypassing preliminary skin tests. However, more severe reactions such as anaphylaxis require skin testing before considering drug provocation tests. For DRESS/AGEP/SJS/TEN, skin tests are useful and safe for identifying culprit drugs. These harmonized methods enable safe drug allergy delabeling while preserving diagnostic accuracy and patient safety. Strict adherence to these standardized protocols is essential to ensure reproducible results and safe clinical practice in drug hypersensitivity evaluation.